Abstract
Of the various possible level of risk at which chemoprevention can be applied 1) premalignant conditions (in the oral cavity: leukoplakia) and 2) patient who have been treated for cancer, but who are at risk to develop a new cancer, are for the upper aerodigestive tract the most important. Studies in oral leukoplakia as well as in the second primary tumors group will be discussed, with emphasis on EUROSCAN. EUROSCAN is an European Organization of Research and Treatment of Cancer (EORTC) chemoprevention study in curatively treated patients with oral cancer, laryngeal cancer and lung cancer which started in 1988; the end of the accrual phase was in 1994. The end of the intervention period is in 1996.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
